vs
Side-by-side financial comparison of Aspire Biopharma Holdings, Inc. (ASBP) and NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI). Click either name above to swap in a different company.
Aspire Biopharma Holdings, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel therapeutic candidates for unmet needs in oncology and rare diseases, with primary operations across North America and key Asia-Pacific markets.
ASBP vs NTHI — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.9K | $0 |
| Net Profit | $-1.9M | $-15.5M |
| Gross Margin | 45.5% | — |
| Operating Margin | -59015.8% | — |
| Net Margin | -95337.1% | — |
| Revenue YoY | — | — |
| Net Profit YoY | -755.6% | — |
| EPS (diluted) | $-0.04 | $-0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $0 | ||
| Q3 25 | $1.9K | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $40.0K |
| Q4 25 | — | $-15.5M | ||
| Q3 25 | $-1.9M | $-8.6M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-32.3M |
| Q4 25 | — | — | ||
| Q3 25 | 45.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -59015.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -79772.0% |
| Q4 25 | — | — | ||
| Q3 25 | -95337.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -80835.2% |
| Q4 25 | — | $-0.35 | ||
| Q3 25 | $-0.04 | $-0.45 | ||
| Q2 25 | — | $-0.30 | ||
| Q1 25 | — | $-2.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $58.7K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-11.5M | $-17.5M |
| Total Assets | $2.4M | $2.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $58.7K | ||
| Q3 25 | — | $1.5M | ||
| Q2 25 | — | $125.0K | ||
| Q1 25 | — | $5.4M |
| Q4 25 | — | $-17.5M | ||
| Q3 25 | $-11.5M | $-11.8M | ||
| Q2 25 | — | $-11.8M | ||
| Q1 25 | — | $-9.6M |
| Q4 25 | — | $2.8M | ||
| Q3 25 | $2.4M | $4.1M | ||
| Q2 25 | — | $3.0M | ||
| Q1 25 | — | $8.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $-3.6M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-3.6M | ||
| Q3 25 | $-1.1M | $-5.8M | ||
| Q2 25 | — | $-5.3M | ||
| Q1 25 | — | $-5.7M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
